AP2907A - Viral hepatitis treatment - Google Patents
Viral hepatitis treatmentInfo
- Publication number
- AP2907A AP2907A AP2008004550A AP2008004550A AP2907A AP 2907 A AP2907 A AP 2907A AP 2008004550 A AP2008004550 A AP 2008004550A AP 2008004550 A AP2008004550 A AP 2008004550A AP 2907 A AP2907 A AP 2907A
- Authority
- AP
- ARIPO
- Prior art keywords
- viral hepatitis
- hepatitis treatment
- treatment
- viral
- hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75703606P | 2006-01-09 | 2006-01-09 | |
PCT/US2007/000574 WO2007081974A2 (en) | 2006-01-09 | 2007-01-09 | Viral hepatitis treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2008004550A0 AP2008004550A0 (en) | 2008-08-31 |
AP2907A true AP2907A (en) | 2014-05-31 |
Family
ID=38257004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2008004550A AP2907A (en) | 2006-01-09 | 2007-01-09 | Viral hepatitis treatment |
Country Status (18)
Country | Link |
---|---|
US (3) | US8633230B2 (de) |
EP (1) | EP1976516B9 (de) |
JP (2) | JP5185826B2 (de) |
CN (1) | CN101448497B (de) |
AP (1) | AP2907A (de) |
AU (1) | AU2007204963B2 (de) |
BR (1) | BRPI0706379A2 (de) |
CA (1) | CA2636527C (de) |
DK (1) | DK1976516T3 (de) |
EA (1) | EA015560B1 (de) |
ES (1) | ES2422556T3 (de) |
HK (1) | HK1123733A1 (de) |
IL (1) | IL192548A (de) |
MX (1) | MX2008008723A (de) |
NZ (1) | NZ569507A (de) |
UA (1) | UA100840C2 (de) |
WO (1) | WO2007081974A2 (de) |
ZA (1) | ZA200806310B (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2604640A1 (en) * | 2005-04-12 | 2006-10-19 | Romark Laboratories L.C. | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
BRPI0706379A2 (pt) | 2006-01-09 | 2011-03-22 | Romark Lab Lc | tratamento de hepatite viral |
WO2009015336A2 (en) * | 2007-07-25 | 2009-01-29 | Biolex Therapeutics, Inc. | Controlled release interferon drug products and treatment of hcv infection using same |
LT2395840T (lt) | 2009-02-13 | 2020-07-10 | Romark Laboratories, L.C. | Nitazoksanido kontroliuojamo atpalaidavimo farmacinės kompozicijos |
AU2010226857B2 (en) | 2009-03-20 | 2016-07-14 | University Of Virginia Patent Foundation | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials |
CA2940954A1 (en) | 2009-05-12 | 2010-11-18 | Romark Laboratories L.C. | Nitazoxanide and tizoxanide for the treatment of rhinovirus and rhabdovirus infections |
BR122020003634B8 (pt) | 2009-06-26 | 2021-07-27 | Romark Laboratories Lc | uso de nitazoxanida, tizoxanida ou sal farmaceuticalmente aceitável do mesmo no tratamento de uma doença semelhante a influenza |
US9333193B2 (en) | 2010-09-20 | 2016-05-10 | University Of Virginia Patent Foundation | Compositions and methods for treating tuberculosis |
US20120294831A1 (en) * | 2011-05-16 | 2012-11-22 | Romark Laboratories L.C. | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections |
CN102805747B (zh) * | 2011-06-01 | 2013-09-18 | 漳州片仔癀药业股份有限公司 | 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途 |
AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
CH707029B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon. |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
BR112014018149B1 (pt) | 2012-01-27 | 2020-09-29 | Siegfried Rhein S.A. De C.V | Composição farmacêutica de nitazoxanida |
BR112017009651A2 (pt) | 2014-11-11 | 2017-12-19 | Romark Laboratories Lc | composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer. |
US20180098972A1 (en) | 2015-01-26 | 2018-04-12 | Children's Medical Center Corporation | Treatment of infectious diseases |
WO2017173056A1 (en) | 2016-03-31 | 2017-10-05 | Romark Laboratories L.C. | Thiazolide compounds for treating viral infections |
JP2019513762A (ja) * | 2016-04-11 | 2019-05-30 | ジェンフィGenfit | 胆汁うっ滞及び線維症の処置方法 |
KR102431257B1 (ko) * | 2016-04-11 | 2022-08-10 | 장피트 | 담즙정체성 및 섬유증 질환의 치료 방법 |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
US11090289B2 (en) | 2017-01-24 | 2021-08-17 | University Of Virginia Patent Foundation | Compositions and methods for blocking sodium channels |
US11033534B2 (en) * | 2017-01-27 | 2021-06-15 | Genfit | Pharmaceutical compositions for combination therapy |
CA3054103A1 (en) * | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
WO2018195035A1 (en) | 2017-04-18 | 2018-10-25 | Romark Laboratories L.C. | Inhibition of protein disulfide-isomerase a3 |
AU2018368611B2 (en) | 2017-11-17 | 2023-12-14 | KÖSTER, Hubert | (2-((5-nitro-1,3-thiazol-2-yl)carbamoyl)phenyl)ethanoate for use in lymphangioleiomyomatosis and other diseases |
CN109364067B (zh) * | 2018-11-17 | 2020-07-28 | 王海玲 | 一种化合物在制备提高血脑屏障通透性药物中的用途 |
EP3952868A1 (de) * | 2019-04-09 | 2022-02-16 | Genfit | Kombination aus nitazoxanid und elafibranor zur behandlung von immunerkrankungen oder entzündungen |
WO2021016543A1 (en) * | 2019-07-25 | 2021-01-28 | Romark Laboratories L.C. | Antiviral combinations of thiazolide compounds |
CN111012788B (zh) * | 2019-12-12 | 2021-01-15 | 武汉职业技术学院 | 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用 |
US20230303504A1 (en) | 2020-07-20 | 2023-09-28 | Romark Laboratories, L.C. | Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine |
MX2023002208A (es) | 2020-08-24 | 2023-05-17 | Romark Laboratories Lc | Uso de tiazolidas contra los coronavirus. |
CN114259492A (zh) * | 2021-12-21 | 2022-04-01 | 中以海德人工智能药物研发股份有限公司 | 硝唑尼特在治疗乙肝中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5886013A (en) * | 1994-09-08 | 1999-03-23 | Romark Laboratories, L.C. | Antiviral composition |
US6340696B1 (en) * | 1999-03-31 | 2002-01-22 | The Procter & Gamble Company | Viral treatment |
EP1213029A1 (de) * | 1998-05-15 | 2002-06-12 | Schering Corporation | Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind |
US20040081711A1 (en) * | 2002-10-29 | 2004-04-29 | Rao Janaswamy Madhusudana | alpha-Glucosidase inhibitors from a natural source |
WO2005049065A2 (en) * | 2003-11-19 | 2005-06-02 | Rigel Pharmaceuticals, Inc. | Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
WO2006031566A2 (en) * | 2004-09-09 | 2006-03-23 | Romark Laboratories, L.C. | Halogenated benzamide derivatives |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
GB1440212A (en) | 1973-08-29 | 1976-06-23 | Phavic Sprl | Derivatives of 2-phenoxyacetamido-5-nitrothiazoles |
US4315018A (en) | 1978-12-07 | 1982-02-09 | Rossignol Jean F | Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives |
US5578621A (en) | 1994-09-08 | 1996-11-26 | Romark Lab Lc | Benzamide derivatives |
US5387598A (en) | 1994-04-13 | 1995-02-07 | Rossignol; Jean-Francois | Composition and galenic formulation suitable for combatting affections of the lower abdomen |
DE69526936T2 (de) | 1994-04-13 | 2003-02-20 | Romark Lab Lc | Benzamide-derivate, zubereitungen die sie erhalten und ihre anwendung |
US5856348A (en) | 1994-09-08 | 1999-01-05 | Romark Laboratories, L.C. | Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide |
US5859038A (en) | 1994-09-08 | 1999-01-12 | Romark Laboratories, L.C. | Method for treatment of helicobacter pylori infections |
US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
US5965590A (en) | 1994-09-08 | 1999-10-12 | Romark Lab Lc | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
NZ500149A (en) * | 1997-05-07 | 2001-11-30 | Romark Lab L | Pharmaceutical compositions containing tizoxanide and/or nitazoxinade |
US5935591A (en) | 1998-01-15 | 1999-08-10 | Romark Laboratories, L.C. | Method for treatment of equine protozoal myeloencephalitis with thiazolides |
US5925622A (en) | 1998-07-13 | 1999-07-20 | Romark Laboratories, L.C. | Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same |
US6180136B1 (en) | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
US7125568B2 (en) | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
EP1562617B1 (de) | 2002-10-29 | 2006-12-20 | Council of Scientific and Industrial Research | Neue verwendung von pipatalin |
WO2005028511A2 (en) * | 2003-03-28 | 2005-03-31 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
US20060194853A1 (en) | 2004-10-08 | 2006-08-31 | Rossignol Jean F | Alkyl benzamides |
CA2604640A1 (en) | 2005-04-12 | 2006-10-19 | Romark Laboratories L.C. | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
BRPI0706379A2 (pt) * | 2006-01-09 | 2011-03-22 | Romark Lab Lc | tratamento de hepatite viral |
LT2395840T (lt) * | 2009-02-13 | 2020-07-10 | Romark Laboratories, L.C. | Nitazoksanido kontroliuojamo atpalaidavimo farmacinės kompozicijos |
-
2007
- 2007-01-09 BR BRPI0706379-2A patent/BRPI0706379A2/pt active Search and Examination
- 2007-01-09 UA UAA200810179A patent/UA100840C2/ru unknown
- 2007-01-09 AU AU2007204963A patent/AU2007204963B2/en not_active Ceased
- 2007-01-09 DK DK07717773.1T patent/DK1976516T3/da active
- 2007-01-09 US US11/651,672 patent/US8633230B2/en active Active
- 2007-01-09 MX MX2008008723A patent/MX2008008723A/es active IP Right Grant
- 2007-01-09 CN CN2007800077942A patent/CN101448497B/zh not_active Expired - Fee Related
- 2007-01-09 EP EP07717773.1A patent/EP1976516B9/de not_active Not-in-force
- 2007-01-09 JP JP2008549616A patent/JP5185826B2/ja not_active Expired - Fee Related
- 2007-01-09 ZA ZA200806310A patent/ZA200806310B/xx unknown
- 2007-01-09 CA CA2636527A patent/CA2636527C/en not_active Expired - Fee Related
- 2007-01-09 ES ES07717773T patent/ES2422556T3/es active Active
- 2007-01-09 AP AP2008004550A patent/AP2907A/xx active
- 2007-01-09 WO PCT/US2007/000574 patent/WO2007081974A2/en active Application Filing
- 2007-01-09 NZ NZ569507A patent/NZ569507A/en not_active IP Right Cessation
- 2007-01-09 EA EA200870164A patent/EA015560B1/ru unknown
-
2008
- 2008-06-30 IL IL192548A patent/IL192548A/en active IP Right Grant
-
2009
- 2009-04-07 HK HK09103295.7A patent/HK1123733A1/xx not_active IP Right Cessation
- 2009-12-24 JP JP2009293398A patent/JP2010070566A/ja active Pending
-
2013
- 2013-12-20 US US14/137,280 patent/US9107913B2/en not_active Ceased
-
2017
- 2017-07-07 US US15/644,637 patent/USRE47404E1/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5886013A (en) * | 1994-09-08 | 1999-03-23 | Romark Laboratories, L.C. | Antiviral composition |
EP1213029A1 (de) * | 1998-05-15 | 2002-06-12 | Schering Corporation | Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind |
US6340696B1 (en) * | 1999-03-31 | 2002-01-22 | The Procter & Gamble Company | Viral treatment |
US20040081711A1 (en) * | 2002-10-29 | 2004-04-29 | Rao Janaswamy Madhusudana | alpha-Glucosidase inhibitors from a natural source |
WO2005049065A2 (en) * | 2003-11-19 | 2005-06-02 | Rigel Pharmaceuticals, Inc. | Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
WO2006031566A2 (en) * | 2004-09-09 | 2006-03-23 | Romark Laboratories, L.C. | Halogenated benzamide derivatives |
Non-Patent Citations (2)
Title |
---|
ROMARK LABORATORIES: "Alinia(R) (nitazoxanide) as New Treatment for Chronic Hepatitis C" NATAP, [Online] 10 January 2006 (2006-01-10) * |
ROSSIGNOL JEAN F ET AL: "Nitazoxanide in treating chronic hepatitis C: in vitro activity and a clinical case report" GASTROENTEROLOGY, vol. 130, no. 4, Suppl. 2, April 2006 (2006-04), page A841, XP009121092 & DIGESTIVE DISEASE WEEK MEETING/107TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; LOS ANGELES, CA, USA; MAY 19 24 * |
Also Published As
Publication number | Publication date |
---|---|
DK1976516T3 (da) | 2013-07-15 |
WO2007081974A3 (en) | 2008-01-17 |
CA2636527C (en) | 2016-05-17 |
UA100840C2 (ru) | 2013-02-11 |
US9107913B2 (en) | 2015-08-18 |
CN101448497B (zh) | 2013-07-10 |
HK1123733A1 (en) | 2009-06-26 |
US8633230B2 (en) | 2014-01-21 |
MX2008008723A (es) | 2008-09-26 |
EP1976516A2 (de) | 2008-10-08 |
IL192548A (en) | 2015-08-31 |
AU2007204963B2 (en) | 2012-09-27 |
ES2422556T3 (es) | 2013-09-12 |
US20140112888A1 (en) | 2014-04-24 |
EP1976516A4 (de) | 2009-11-11 |
CA2636527A1 (en) | 2007-07-19 |
US20070167504A1 (en) | 2007-07-19 |
EA200870164A1 (ru) | 2008-12-30 |
EP1976516B9 (de) | 2013-10-30 |
USRE47404E1 (en) | 2019-05-28 |
IL192548A0 (en) | 2009-02-11 |
AU2007204963A1 (en) | 2007-07-19 |
BRPI0706379A2 (pt) | 2011-03-22 |
EA015560B1 (ru) | 2011-08-30 |
EP1976516B1 (de) | 2013-04-24 |
JP2010070566A (ja) | 2010-04-02 |
ZA200806310B (en) | 2009-12-30 |
JP2009522371A (ja) | 2009-06-11 |
WO2007081974A2 (en) | 2007-07-19 |
CN101448497A (zh) | 2009-06-03 |
AP2008004550A0 (en) | 2008-08-31 |
JP5185826B2 (ja) | 2013-04-17 |
NZ569507A (en) | 2011-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2907A (en) | Viral hepatitis treatment | |
HRP20160410T8 (hr) | Inhibitori hepatitis c virusa | |
AP2880A (en) | Novel viral factor | |
IL198087A0 (en) | Methods of inactivating viruses | |
IL194920A0 (en) | Hepatitis c virus infection biomarkers | |
EP2062246A4 (de) | Impfstoffe gegen chimärische viren | |
HK1144440A1 (en) | Hepatitis c virus antibodies | |
EP2120988A4 (de) | Behandlung von hepatitis-c-virusinfektionen | |
IL213593A0 (en) | Hepatitis c virus combination therapy | |
GB0416487D0 (en) | Modified virus | |
HUE026600T2 (hu) | Készítmények és eljárások virális hepatitis kezelésére | |
PL2049153T3 (pl) | Atenuowane wirusy polio | |
GB0720624D0 (en) | Viral Modification | |
EP2004684A4 (de) | Das hepatitis-c-virus neutralisierende antikörper | |
ZA200903379B (en) | Hepatitis C virus inhibitors | |
GB0617694D0 (en) | Viral inactivation | |
GB0520800D0 (en) | Viral treatment | |
HUS1500008I1 (hu) | Hepatitis C vírus inhibitorok | |
GB0617310D0 (en) | Treatment of hepatitis c | |
ZA200903014B (en) | Hepatitis C virus inhibitors | |
GB0717139D0 (en) | Treatment of hepatitis C | |
GB0716850D0 (en) | Viral inactivation | |
GB0518798D0 (en) | Viral inactivation | |
GB0709027D0 (en) | Virus purification | |
GB0508061D0 (en) | RNA viruses |